TMRW Life Sciences Closes $25M Series B Funding


TMRW Life Sciences, a creator of an integrated platform for automated, software-guided embryology and cryo-management, closed a $25m Series B funding.

The round was led by 5AM Ventures.

Led by Co-CEOs Alan Murray and Joshua Abram, TMRW provides a physical and digital chain of custody, protecting and tracking eggs, embryos, and sperm through RFID-enabled technology. The company’s SaaS digital chain of custody platform is designed to eliminate the sample management issues reported in the fertility space, including loss of eggs and embryos through human error and implantation mix-ups.

Its five leading clinic partners, who account for 10% of all U.S. IVF activity, are preparing for a commercial rollout in Q1 2020. With the announcement of the closing of the Series B, TMRW appointed Melanie Goldey as its Chief Operating Officer and Chief Financial Officer.

Prior to joining TMRW, Goldey was the CFO of Refinery29, a diversified media brand for women. The third co-founder of the company is Dr. Jeffrey Port.



Join the discussion